The U.S. Food and Drug Administration (FDA) announced Wednesday that it has approved the marketing of 23andMe’s reports on pharmacogenetics, which the genetic-testing company claims are designed to assess whether genetics may affect an individual’s ability to metabolize certain drugs including antidepressants.
Source: Gizmodo – FDA Approves New 23andMe Pharmacogenetic Reports, But There Are Some Caveats